News

GlobalData on MSN12h
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This authorisation makes the amyloid-beta (Aβ) ...
Radio Free Europe/Radio Liberty1h
Russian Attack On Dnipro Kills 2 Women, Injures At Least 16
A Russian drone attack killed young woman and an elderly woman and injured at least 16 others on April 16 in the southeastern ...
Radio Free Europe/Radio Liberty10h
Kyiv Cites 'Significant Progress' In Talks With US On Partnership Deal, Rare Earth Minerals
Ukrainian Economy Minister Yulia Svyrydenko said there has been "significant progress" in negotiations with the United States ...
PharmiWeb15h
Leqembi® (lecanemab) is the First Medicine that…
Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...
PipelineReview.com15h
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...